The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase
Emiel J. Rutgers(Oncode Institute), Fátima Cardoso(Breast Cancer Alliance), Jean‐Yves Pierga(Université Paris Cité), Alastair M. Thompson(Baylor College of Medicine), Isabel T. Rubio(Clinica Universidad de Navarra), A. Vindevoghel(Clinique Saint-Joseph), Rodolfo Passalacqua(Champalimaud Foundation), Jan Bogaerts(European Organisation for Research and Treatment of Cancer), Peter M. Ravdin(The University of Texas MD Anderson Cancer Center), Gustavo Werutsky(European Organisation for Research and Treatment of Cancer), Suzette Delaloge(Institut Gustave Roussy), Martine Piccart(Université Libre de Bruxelles), Ulrike Nitz(Women‘s Healthcare Group), Giuseppe Viale(University of Milan), Laura van ‘t Veer
Cited by 105
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k